USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

Download PDF Copy

Nov 24 2010

NewsGuard 100/100 Score

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.

These generic duloxetine hydrochloride delayed-release capsules, 20 mg (base), 30 mg (base), and 60 mg (base) are indicated in the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) and Diabetic Peripheral Neuropathic Pain (DPNP).

Cymbalta® has annual sale of approximately $ 3 billion in the US.

Cymbalta® is a registered trademark of Eli Lilly & Company.

SOURCE Sun Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anxiety, Anxiety Disorder, Cardiology, Cymbalta, Depressive Disorder, Duloxetine, Generalized Anxiety Disorder (GAD), Major Depressive Disorder, Neurology, Neuropathic Pain, New Drug Application, Pain, Pharmaceuticals, Psychiatry

Comments (0)

Download PDF Copy

Suggested Reading

Accelerating tobacco decline could boost global life expectancy

Accelerating tobacco decline could boost global life expectancy

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

New biomarkers offer hope for early detection and prevention of Alzheimer's

New biomarkers offer hope for early detection and prevention of Alzheimer's

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Study focuses on COPD progression in younger populations